Sign In
Buy XENE
$53.46
+1.16 (+2.22%)
At Close: Jun 03, 2026
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:55pm, Friday, 01'st Aug 2025
VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developi
Xenon Joins the Russell 3000® and Russell 2000® Indexes
04:01pm, Friday, 27'th Jun 2025
VANCOUVER, British Columbia and BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developi
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 26'th Jun 2025
VANCOUVER, British Columbia and BOSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developi
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
08:30am, Tuesday, 24'th Jun 2025
Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications Mr. Cline br
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
12:36pm, Wednesday, 11'th Jun 2025
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock?
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
04:01pm, Tuesday, 03'rd Jun 2025
VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developi
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 30'th May 2025
VANCOUVER, British Columbia and BOSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developin
Polarean's Xenon MRI technology to feature in over 30 studies at American Thoracic Society events
11:36am, Thursday, 15'th May 2025
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF), the AIM-listed medical imaging company, will have its Xenon-based magnetic resonance imaging (MRI) technology showcased in more than 30 clinical studies at
Xenon MRI Featured Prominently at ATS 2025 Across Broad Clinical Spectrum
08:49am, Thursday, 15'th May 2025
30+ studies across diverse conditions illuminate the unique value of functional lung imaging with Xenon MRI 30+ studies across diverse conditions illuminate the unique value of functional lung imaging
Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference
04:01pm, Wednesday, 14'th May 2025
VANCOUVER, British Columbia and BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developin
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
01:10pm, Tuesday, 13'th May 2025
XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.
Xenon Pharmaceuticals Inc. (XENE) Q1 2025 Earnings Call Transcript
10:06pm, Monday, 12'th May 2025
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 AM ET Corporate Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
04:01pm, Monday, 12'th May 2025
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026
Xenon to Report Q1 2025 Financial Results on May 12, 2025
04:01pm, Monday, 05'th May 2025
VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developin
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?
11:01am, Monday, 05'th May 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 48.2% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionab
